Moomoo AIのまとめ
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce...Show More
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce operational expenditures, including labor expense reductions and facility consolidations, expected to commence in the second quarter of 2024. Additionally, Ginkgo acquired platform assets from AgBiome, Inc. on April 10, 2024, to enhance its Ag Biologicals Services. Looking forward, Ginkgo Bioworks aims to leverage its Foundry and Codebase assets to drive scale and learning efficiencies across diverse markets, with a focus on improving the probability of successful product development for its customers.
2024年3月31日に終了した第1四半期の総売上高が減少し、売上高が8007.02万ドルから3,794.4万ドルに減少したGinkgo Bioworks Holdings, Inc. 。同社の細胞工学セグメントは、3409.6万ドルから2,788.9万ドルに、Biosecurityセグメントの売上高は4660.6万ドルから1005.5万ドルに大幅に減少した。総セグメントオペレーティング損失は、前年比で1億2366.2万ドルから1億1641万ドルに拡大した。希薄化後の1株あたりの純損失は$0.08であり、前年と同様、前年の1株あたりの純損失$0.11から改善した。Ginkgo Bioworksは...すべて展開
2024年3月31日に終了した第1四半期の総売上高が減少し、売上高が8007.02万ドルから3,794.4万ドルに減少したGinkgo Bioworks Holdings, Inc. 。同社の細胞工学セグメントは、3409.6万ドルから2,788.9万ドルに、Biosecurityセグメントの売上高は4660.6万ドルから1005.5万ドルに大幅に減少した。総セグメントオペレーティング損失は、前年比で1億2366.2万ドルから1億1641万ドルに拡大した。希薄化後の1株あたりの純損失は$0.08であり、前年と同様、前年の1株あたりの純損失$0.11から改善した。Ginkgo Bioworksは、労働費の削減、施設の統合など、運営費を削減するための再構築措置を実施し、2024年第2四半期に開始する予定です。さらに、Ginkgoは2024年4月10日にAgBiome, Inc.からプラットフォームアセットを取得し、Ag Biologicalsサービスを強化しました。今後、Ginkgo Bioworksは、FoundryおよびCodebaseアセットを活用して、多様な市場でスケールと学習効率を高め、顧客の製品開発の成功確率を高めることを目指しています。
役に立った
役に立たない